Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for corticosteroid-unresponsive pre-engraftment syndrome after unrelated cord blood transplantation
ChiCTR1800015472Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in pre-engraftment syndrome (PES), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Body temperature and 180-day transplant-related mortality. Started Apr 2018; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
pre-engraftment syndrome (PES)
Beyond the preview
Go deeper on ChiCTR1800015472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015472.